1
|
Maerevoet M, Casasnovas O, Cartron G, Morschhauser F, Thieblemont C, Bouabdallah K, Feugier P, Szablewski V, Becker S, Tilly H. SELINEXOR IN COMBINATION WITH R‐GDP FOR PATIENTS WITH RELAPSED/REFRACTORY B‐CELL LYMPHOMA: PRELIMINARY RESULTS OF THE SELINDA PHASE IB LYSA STUDY ( EUDRACT NUMBER: 2015‐005612‐15). Hematol Oncol 2021. [DOI: 10.1002/hon.88_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- M. Maerevoet
- Institut Jules Bordet ULB, Hematology Brussels Belgium
| | - O. Casasnovas
- CHU Dijon Bourgogne Hematology and INSERM 1231 Dijon France
| | - G. Cartron
- CHU Montpellier Hematology Montpellier France
| | | | | | | | | | - V. Szablewski
- CHU Montpellier Pathological Anatomy and Cytology Montpellier France
| | - S. Becker
- Centre Henri Becquerel Nuclear Medicine Rouen France
| | - H. Tilly
- Centre Henri Becquerel Hematology Rouen France
| |
Collapse
|
2
|
Menguy S, Mansour Y, Augereau O, Ortonne N, Balme B, Battistella M, Lamant L, Beltzung F, Szablewski V, Gaulard P, Bagot M, Beylot-Barry M, Vergier B. Impact des algorithmes du Groupe Français d’Étude des Lymphomes Cutanés sur le diagnostic anatomopathologique des lymphoproliférations cutanées. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
3
|
Sonigo G, Battistella M, Beylot-Barry M, Oro S, Franck N, Barete S, Boulinguez S, Dereure O, Bonnet N, Socié G, Brice P, Boccara O, Bodemer C, Adamski H, D’Incan M, Ortonne N, Fraitag S, Brunet-Possenti F, Dalle S, Suarez F, Marcais A, Skowron F, Haidar D, Maubec E, Bohelay G, Laroche L, Mahé A, Birckel E, Bouaziz JD, Brocheriou I, Dubois R, Faiz S, Fadlallah J, Ram-Wolff C, Carlotti A, Bens G, Balme B, Vergier B, Laurent-Roussel S, Deschamps L, Carpentier O, Moguelet P, Hervé G, Comoz F, Le Gall F, Leverger G, Finon A, Augereau O, Bléchet C, Kerdraon R, lamant L, Tournier E, Franck F, Costes-Martineau V, Szablewski V, Taix S, Beschet I, Guérin F, Sepulveda F, Bagot M, De Saint-Basile G, Michonneau D, De Masson A. Étude clinique à long terme et mutations HAVCR2 chez 70 patients atteints de lymphome T sous cutané à type de panniculite. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
4
|
Müller I, Ramis-Zaldívar J, Schmidt J, Egan C, Gonzalez-Farre B, Salmeron-Villalobos J, Mattern S, Szablewski V, Dojcinov S, Chott A, Copie-Bergman C, Bonzheim I, Campo E, Fend F, Jaffe E, Salaverria I, Quintanilla de Fend L. GENOME WIDE-ANALYSIS OF T(14;18)-NEGATIVE FOLLICULAR LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.102_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- I. Müller
- Institute of Pathology; University Hospital Tübingen, Eberhard-Karls-University of Tübingen; Tübingen Germany
| | - J. Ramis-Zaldívar
- Hematopathology Unit; Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERONC, Universitat de Barcelona; Barcelona Spain
| | - J. Schmidt
- Institute of Pathology; University Hospital Tübingen, Eberhard-Karls-University of Tübingen; Tübingen Germany
| | - C. Egan
- Laboratory of Pathology; Center for Cancer Research, National Cancer Institute, National Institutes of Health; Maryland United States
| | - B. Gonzalez-Farre
- Hematopathology Unit; Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERONC, Universitat de Barcelona; Barcelona Spain
| | - J. Salmeron-Villalobos
- Hematopathology Unit; Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERONC, Universitat de Barcelona; Barcelona Spain
| | - S. Mattern
- Institute of Pathology; University Hospital Tübingen, Eberhard-Karls-University of Tübingen; Tübingen Germany
| | - V. Szablewski
- Département de Biopatholog Cellulaire et Tissulaire des Tumeurs; CHU Montpellier, Hôpital Gui De Chauliac; Montpellier France
| | - S. Dojcinov
- Department of Pathology; University Hospital of Wales; Cardiff United Kingdom
| | - A. Chott
- Institute of Pathology and Microbiology; Wilhelminenspital; Vienna Austria
| | - C. Copie-Bergman
- Department of Pathology; Henri Mondor Hospital, APHP, INSERM U955, Université Paris-Est; Créteil France
| | - I. Bonzheim
- Institute of Pathology; University Hospital Tübingen, Eberhard-Karls-University of Tübingen; Tübingen Germany
| | - E. Campo
- Hematopathology Unit; Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERONC, Universitat de Barcelona; Barcelona Spain
| | - F. Fend
- Institute of Pathology; University Hospital Tübingen, Eberhard-Karls-University of Tübingen; Tübingen Germany
| | - E.S. Jaffe
- Laboratory of Pathology; Center for Cancer Research, National Cancer Institute, National Institutes of Health; Maryland United States
| | - I. Salaverria
- Hematopathology Unit; Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERONC, Universitat de Barcelona; Barcelona Spain
| | - L. Quintanilla de Fend
- Institute of Pathology; University Hospital Tübingen, Eberhard-Karls-University of Tübingen; Tübingen Germany
| |
Collapse
|
5
|
Mollaret E, Gomez E, Nadel B, Naiglin L, Anquetin M, Barau C, Baseggio L, Bret C, Brisou G, Brousset P, Camara-Clayette V, Cartron G, Da Cunha K, Dartigues P, Dupuis J, Ghaleh B, Gravelle P, Houot R, Karmous-Gadacha O, Laurent C, Moreaux J, Pangault C, Ribrag V, Salles G, Szablewski V, Thouault V, Uze G, Verge V, Ysebaert L, Gaulard P, Fest T. CeVi: A UNIQUE CRYOPRESERVED HUMAN VIABLE CELL COLLECTION FROM LYMPHOMA PATIENTS, A CALYM INITIATIVE TO ACCELERATE INNOVATION AND ITS TRANSFER TO LYMPHOMA FIELD. Hematol Oncol 2019. [DOI: 10.1002/hon.38_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- E. Mollaret
- R&D; Carnot CALYM Institute; Pierre-Bénite France
| | - E. Gomez
- R&D; Carnot CALYM Institute; Pierre-Bénite France
| | - B. Nadel
- R&D; Carnot CALYM Institute; Pierre-Bénite France
| | - L. Naiglin
- R&D; Carnot CALYM Institute; Pierre-Bénite France
| | - M. Anquetin
- Plateforme de Ressources Biologiques; APHP - Hôpitaux Universitaires Henri Mondor; Créteil France
| | - C. Barau
- Plateforme de Ressources Biologiques; APHP - Hôpitaux Universitaires Henri Mondor; Créteil France
| | - L. Baseggio
- Laboratoire d'Hématologie; Groupement Hospitalier Sud/Hospices Civils de Lyon; Pierre-Bénite France
| | - C. Bret
- Hématologie Biologique; CHU Montpellier; Montpellier France
| | - G. Brisou
- Hématologie Clinique; Groupement Hospitalier Sud/ Hospices Civils de Lyon; Pierre-Bénite France
| | - P. Brousset
- Pathology and Cytology Department; UMR1037 Centre de Recherche en Cancerologie de Toulouse, CHU Toulouse, IUCT Oncopole / Toulouse III Paul Sabatier University / Inserm; Toulouse France
| | - V. Camara-Clayette
- Laboratoire RT Hématologie (AMMICa INSERM US23/CNRS UMS3655); Gustave Roussy; Villejuif France
| | - G. Cartron
- Département d'Hématologie Clinique; CHU Montpellier; Montpellier France
| | - K. Da Cunha
- CRB Sud; Groupement Hospitalier Sud/ Hospices Civils de Lyon; Pierre-Bénite France
| | - P. Dartigues
- Département de Biologie et Pathologie Médicales - Service de pathologie Morphologique; Gustave Roussy; Villejuif France
| | - J. Dupuis
- Unité Hémopathies Lymphoïdes; APHP - Hôpitaux Universitaires Henri Mondor; Créteil France
| | - B. Ghaleh
- Plateforme de Ressources Biologiques; APHP - Hôpitaux Universitaires Henri Mondor; Créteil France
| | - P. Gravelle
- Pathology and Cytology Department; UMR1037 Centre de Recherche en Cancerologie de Toulouse, CHU Toulouse, IUCT Oncopole / Toulouse III Paul Sabatier University / Inserm; Toulouse France
| | - R. Houot
- Hématologie; CHU Rennes - Pontchaillou; RENNES France
| | | | - C. Laurent
- Pathology and Cytology Department; UMR1037 Centre de Recherche en Cancerologie de Toulouse, CHU Toulouse, IUCT Oncopole / Toulouse III Paul Sabatier University / Inserm; Toulouse France
| | - J. Moreaux
- Hématologie Biologique; CHU Montpellier; Montpellier France
| | - C. Pangault
- UMR-S 1236 / Laboratoire Hématologie; Université de Rennes I / CHU Rennes; Rennes France
| | - V. Ribrag
- Laboratoire RT Hématologie (AMMICa INSERM US23/CNRS UMS3655); Gustave Roussy; Villejuif France
| | - G. Salles
- Hématologie Clinique; Hospices Civils de Lyon / Université Claude Bernard; Pierre Bénite France
| | - V. Szablewski
- Pathologie et Oncobiologie; CHU Montpellier; Montpellier France
| | - V. Thouault
- Laboratoire d'hématologie; CHU Rennes - Pontchaillou; Rennes France
| | - G. Uze
- UMR 5235; CNRS / University Montpellier; Montpellier France
| | - V. Verge
- Département de Biologie et Pathologie Médicales - Laboratoire d'hématologie; Gustave Roussy; Villejuif France
| | - L. Ysebaert
- Hématologie; IUC-Toulouse Oncopole; Toulouse France
| | - P. Gaulard
- Department of Pathology; AP-HP; Créteil France
| | - T. Fest
- UMR-S 1236 / Laboratoire Hématologie; Université de Rennes I / CHU Rennes; Rennes France
| |
Collapse
|
6
|
Bontoux C, De Masson A, Boccara O, Bodemer C, Fraitag S, Balme B, Franck N, Carlotti A, Comoz F, Verneuil L, Brasme JF, Duplan M, Croué A, Templier I, Beltraminelli H, Dereure O, Szablewski V, Thevenin C, Boulinguez S, Viraben R, Tournier E, Lamant L, Ortonne N, Ingen-Housz-Oro S, Beckerich F, Grange F, Durlach A, Amatore F, Frouin E, McIntyre E, Asnafi V, Kim R, Clappier E, Soulier J, Boissel N, Dombret H, Bagot M, Battistella M. Clinical aspects and outcome of lymphoblastic leukemia/lymphoma with cutaneous involvement. Eur J Cancer 2019. [DOI: 10.1016/s0959-8049(19)30538-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
7
|
Bozon A, Dereure O, Szablewski V, Vincent T, Thanh AD, Gustave V. Lymphome à grandes cellules ALK1 négatif CD 30+ avec atteintes ganglionnaire et cutanée sous dupilumab. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.430] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
8
|
Malissen N, Szablewski V, Eberst E, Merlet-Albrand S, Jeziorski E, Dereure O. Manifestations cutanées associées à un syndrome lymphoprolifératif avec auto-immunité : 1er cas rapporté. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
9
|
Vincent L, Ceballos P, Plassot C, Méniane JC, Quittet P, Navarro R, Cyteval C, Szablewski V, Lu ZY, Kanouni T, Moreaux J, Cartron G, Klein B, Fegueux N. Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma. Blood Cancer J 2015; 5:e341. [PMID: 26295611 PMCID: PMC4558584 DOI: 10.1038/bcj.2015.48] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Affiliation(s)
- L Vincent
- Département d'Hématologie Clinique, CHRU de Montpellier, Montpellier, France.,Université MONTPELLIER 1, UFR de Médecine, Montpellier, France.,Laboratoire de Biostatistiques, IURC, Montpellier, France
| | - P Ceballos
- Département d'Hématologie Clinique, CHRU de Montpellier, Montpellier, France
| | - C Plassot
- Université MONTPELLIER 1, UFR de Médecine, Montpellier, France.,Laboratoire de Biostatistiques, IURC, Montpellier, France
| | - J C Méniane
- Département d'Hématologie Clinique, CHRU de Montpellier, Montpellier, France
| | - P Quittet
- Département d'Hématologie Clinique, CHRU de Montpellier, Montpellier, France
| | - R Navarro
- Département d'Hématologie Clinique, CHRU de Montpellier, Montpellier, France
| | - C Cyteval
- Département d'Imagerie Médicale CHRU de Montpellier, Montpellier, France
| | - V Szablewski
- Département d'Anatomopathologie, CHRU de Montpellier, Montpellier, France
| | - Z Y Lu
- Unité de Thérapie Cellulaire, CHRU de Montpellier, Montpellier, France
| | - T Kanouni
- Département d'Hématologie Clinique, CHRU de Montpellier, Montpellier, France
| | - J Moreaux
- INSERM, U1040, Montpellier, France.,Laboratory for Innovative Biology, Department of Biological Hematology, CHRU de Montpellier, Montpellier, France
| | - G Cartron
- Département d'Hématologie Clinique, CHRU de Montpellier, Montpellier, France.,Université MONTPELLIER 1, UFR de Médecine, Montpellier, France.,Laboratoire de Biostatistiques, IURC, Montpellier, France
| | - B Klein
- Université MONTPELLIER 1, UFR de Médecine, Montpellier, France.,Laboratoire de Biostatistiques, IURC, Montpellier, France.,INSERM, U1040, Montpellier, France.,Laboratory for Innovative Biology, Department of Biological Hematology, CHRU de Montpellier, Montpellier, France
| | - N Fegueux
- Département d'Hématologie Clinique, CHRU de Montpellier, Montpellier, France
| |
Collapse
|
10
|
Vilquin P, Dereure O, Bernard-Decot C, Szablewski V, Frouin E, Goze C, Boulle N, Girard C, Guillot B. Étude des mutations BRAF non V600E et des co-mutations BRAF/NRAS/C-KIT dans le mélanome cutané. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
11
|
|
12
|
Merindol N, Riquet A, Szablewski V, Eliaou JF, Puisieux A, Bonnefoy N. Erratum: The emerging role of Twist proteins in hematopoietic cells and hematological malignancies. Blood Cancer J 2014. [PMCID: PMC4220654 DOI: 10.1038/bcj.2014.81] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
13
|
Merindol N, Riquet A, Szablewski V, Eliaou JF, Puisieux A, Bonnefoy N. The emerging role of Twist proteins in hematopoietic cells and hematological malignancies. Blood Cancer J 2014; 4:e206. [PMID: 24769647 PMCID: PMC4003416 DOI: 10.1038/bcj.2014.22] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2014] [Accepted: 03/17/2014] [Indexed: 02/03/2023] Open
Abstract
Twist1 and Twist2 (Twist1–2) are two transcription factors, members of the basic helix-loop-helix family, that have been well established as master transcriptional regulators of embryogenesis and developmental programs of mesenchymal cell lineages. Their role in oncogenesis in epithelium-derived cancer and in epithelial-to-mesenchymal transition has also been thoroughly characterized. Recently, emerging evidence also suggests a key role for Twist1–2 in the function and development of hematopoietic cells, as well as in survival and development of numerous hematological malignancies. In this review, we summarize the latest data that depict the role of Twist1–2 in monocytes, T cells and B lymphocyte activation, and in associated hematological malignancies.
Collapse
Affiliation(s)
- N Merindol
- Université de Lyon and INSERM U1111, Lyon, France
| | - A Riquet
- Université de Lyon and INSERM U1111, Lyon, France
| | - V Szablewski
- 1] IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U896, Université Montpellier 1, Montpellier, France [2] Département de Biopathologie, Centre Hospitalier Régional Universitaire de Montpellier et Faculté de Médecine, Université Montpellier 1, Montpellier, France
| | - J-F Eliaou
- 1] IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U896, Université Montpellier 1, Montpellier, France [2] Département d'Immunologie, Centre Hospitalier Régional Universitaire de Montpellier et Faculté de Médecine, Université Montpellier 1, Montpellier, France
| | - A Puisieux
- Centre de Receherche en Cancérologie de Lyon, INSERM UMR-S1052, Centre Léon Bérard, Lyon, France
| | - N Bonnefoy
- IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U896, Université Montpellier 1, Montpellier, France
| |
Collapse
|
14
|
Amiot A, Lévy M, Copie-Bergman C, Dupuis J, Szablewski V, Le Baleur Y, Baia M, Belhadj K, Sobhani I, Leroy K, Haioun C, Delchier JC. Rituximab, alkylating agents or combination therapy for gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomised observational study. Aliment Pharmacol Ther 2014; 39:619-28. [PMID: 24467480 DOI: 10.1111/apt.12635] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/27/2013] [Revised: 12/14/2013] [Accepted: 01/06/2014] [Indexed: 12/18/2022]
Abstract
BACKGROUND There is no consensus on the standard treatment of gastric mucosa-associated lymphoid tissue (MALT) lymphoma for Helicobacter pylori-negative patients and for patients with persistent disease despite H. pylori eradication. AIM To evaluate the comparative efficacy and safety of alkylating agents and rituximab alone or in combination. METHODS In this monocentric retrospective study, which included 106 patients who had not been previously treated with anti-cancer agents, we evaluated the efficacy and safety of oral alkylating agents monotherapy (n = 48), rituximab monotherapy (n = 28) and the therapy combining both drugs (n = 30). Evaluations were performed at weeks 6 (W6), 25 (W25), and 52 (W52) and after 2 years (W104). RESULTS After a median follow-up period of 4.9 years (range 0.4-17.2 years), complete remission and overall response were significantly higher in patients in the combination therapy group at W104 (92% and 100% respectively) compared with patients treated with alkylating agents alone (66% and 68%) and rituximab alone (64% and 73%). The 5-year progression-free survival probabilities were 68%, 70% and 89% in patients treated with alkylating agents alone, rituximab alone and combination therapy respectively. Haematological adverse events were reported in 32 (30%) patients (mostly grade 1) and were more frequent in the two groups receiving alkylating agents (P = 0.05 and P < 0.001). No toxicity-related death was reported. CONCLUSIONS The use of anti-cancer systemic therapy is safe and efficient in gastric MALT lymphoma. In this retrospective study, the combination of rituximab plus chlorambucil seems more efficient than rituximab or alkylating agents alone. Rituximab has a better safety profile than regimens containing alkylating agents.
Collapse
Affiliation(s)
- A Amiot
- Department of Gastroenterology, Albert Chenevier-Henri Mondor Hospital, Créteil, France; Department of Pathology, Albert Chenevier-Henri Mondor Hospital, Créteil, France; Lymphoid Malignancies Unit, Albert Chenevier-Henri Mondor Hospital, Créteil, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Szablewski V, Garrel R, Gomez-Brouchet A, Laé M, Ranchère-Vince D, Neuville A, Coindre JM, Costes-Martineau V. Sarcomes des fosses nasales et des sinus : une étude clinicopathologique de 52 cas. Ann Pathol 2012. [DOI: 10.1016/j.annpat.2012.09.185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
16
|
Szablewski V, Benlenlih A, Burcia V, Garrel R, Costes V. Comment et pourquoi améliorer l’évaluation du stade ganglionnaire cervical chez les patients présentant un carcinome épidermoïde de la cavité orale ou de l’oropharynx T1 T2 N0 ? Ann Pathol 2011. [DOI: 10.1016/j.annpat.2011.09.087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|